Academic Background It is widely recognized that the cognitive function of patients with high-grade glioma is affected by the location and volume of the tumor. However, research on how to accurately predict individual patients’ cognitive function for personalized treatment decisions before and after surgery remains limited. Currently, most studies ...

Research Report on Claudin 18.2 in Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Background Introduction Gastric cancer and gastroesophageal junction (G/GEJ) adenocarcinoma are major global health burdens. It is estimated that in 2020 alone, there were approximately 1.7 million new cases of gastric and esophageal cancers worldwide, wi...

Study on Real-world Outcomes of First-line Immune Checkpoint Inhibitor Therapy in Metastatic Melanoma Predicted by Tumor Mutational Burden The treatment of metastatic melanoma has significantly benefited from immune checkpoint inhibitors (ICIs) in recent years. However, despite the remarkable improvement in survival rates among melanoma patients, t...

The Use of Regorafenib in Patients with BRAF-Mutant Solid Tumors: A Summary of Results from the TAPUR Study Background Introduction The BRAF gene belongs to the cytoplasmic serine/threonine kinase family and regulates cell proliferation and survival by activating the mitogen-activated protein kinase signaling pathway (MAPK). BRAF mutations can lead...

In contemporary clinical oncology practice and drug development, the methods for evaluating tumor response are on the cusp of a revolution. Since the World Health Organization (WHO) proposed tumor response classification criteria for assessing the effectiveness of anti-cancer drugs in 1981, this field has undergone several improvements. Notably, th...

Transcriptomic Analysis of Prostate Cancer Patients: A Study on Nonlocalized Disease Based on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Academic Background Prostate cancer is a common male malignancy, and its diagnosis and treatment are crucial to patient prognosis. Transcriptomic analysis is a technique us...

Study on the Efficacy of Erdafitinib in Patients with Tumors with FGFR Mutations or Fusions This academic report is based on the scientific paper “Phase II Study of Erdafitinib in Patients with Tumors with Fibroblast Growth Factor Receptor Mutations or Fusions: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2,” and introduces the...

Research Background In recent years, Poly ADP-ribose Polymerase (PARP) inhibitors have shown significant efficacy as a key approach to treat hereditary BRCA1/2 mutation cancers. However, their effectiveness on tumors with other homologous recombination deficiency (HRD) gene mutations such as ATM, CDK12, and CHEK2 has been less satisfactory. Hence, ...

Phase II Study of Erdafitinib in Patients with FGFR Amplifications: A Detailed Report Background Dysregulation of Fibroblast Growth Factor Receptor (FGFR) family signaling pathways is widely recognized to be associated with cancer development, progression, and treatment resistance. This study primarily investigates tumors with FGFR1-4 amplification...

Overall Survival and Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Patients Based on PTEN Status Academic Background Prostate cancer is one of the most common malignant tumors among men worldwide and a leading cause of cancer-related deaths. Approximately 10%-20% of prostate cancer patients will develop castration-resistant ...